aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Fog Pharmaceuticals, founded with the mission to make all disease targets druggable, is a clinical-stage biopharmaceutical company focused on developing cell-penetrating mini-proteins for cancer treatment. Their core product, Helicons™, represents a new class of precision medicines designed to overcome the limitations of current therapies. By integrating advanced technologies, Fog Pharmaceuticals aims to accelerate drug discovery and target previously intractable diseases, with a primary focus on oncology.
Notable figures affiliated with Fog Pharmaceuticals include seasoned biotech entrepreneurs and leading scientists in the field of drug discovery. The company has attracted significant investment from prominent venture capital firms, enabling rapid advancement in their research and development efforts. Key achievements include the development of their proprietary discovery engine and the successful progression of Helicons™ into clinical trials. Fog Pharmaceuticals' innovative approach has the potential to significantly impact cancer treatment and broaden the scope of precision medicine.
Operating Status
Active
Ownership Type(s)
Venture Capital, Equity
Main Product(s)
Drug Discovery, Cancer Treatment
Technology
Biotech
Tags
Healthtech
Model Types
Platform, Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Fog Pharmaceuticals founded?
Fog Pharmaceuticals was founded in 2015.
Where is Fog Pharmaceuticals's headquarters located?
Fog Pharmaceuticals's headquarters is located in Cambridge, MA, US.
When was Fog Pharmaceuticals's last funding round?
Fog Pharmaceuticals's most recent funding round was for $178M (USD) in November 2022.
How many employees does Fog Pharmaceuticals have?
Fog Pharmaceuticals has 147 employees as of Feb 5, 2024.
How much has Fog Pharmaceuticals raised to-date?
As of July 05, 2023, Fog Pharmaceuticals has raised a total of $385.3M (USD) since Nov 21, 2022.
Add Comparison
Total Raised to Date
$385.3M
USD
Last Update Nov 21, 2022
Last Deal Details
$178M
USD
Nov 21, 2022
Series D
Total Employees Over Time
147
As of Feb 2024
Fog Pharmaceuticals Address
100 Acorn Park Drive
6th Floor
Cambridge,
Massachusetts
02140
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts